Immunic Therapeutics

Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies.

51-100 employees
Biotechnology
Public Company

Open Positions11

Remote - USFull-TimeBiotechnology and pharmaceuticalsPosted
  • Own HCP and organized customer/access segment strategy, aligned with brand strategy and a core narrative adaptable across US and international markets.
  • Translate clinical and mechanism-of-action data into differentiated brand messaging relevant to physicians.
  • Apply lessons from prior global MS launches to launch sequencing, market prioritization, and pre-launch disease education.
  • Lead end-to-end omnichannel and digital execution across web, social, and non-personal promotion.
  • Partner on market research, launch scenarios, segmentation, targeting, and KPIs using insights and analytics.
  • Partner with Market Access on integrated plans for payers, population-based decision makers, and practice managers; own pull-through strategy and resources.
  • Coordinate with Market Access, Medical Affairs, Patient Advocacy, Regulatory, and Legal/Compliance on launch readiness.
  • Build and manage the HCP and access marketing budget with marketing peers, Access, Finance, and the VP of Marketing.
  • Onboard and manage creative, media, research, and digital agencies, and develop scalable marketing processes and governance.
Market ResearchDigital Marketing
Showing 1 of 11 positions

Overview

Immunic Therapeutics is a clinical-stage biopharmaceutical company that develops selective oral immunology therapies for chronic inflammatory and autoimmune diseases. The company is developing three small molecule product candidates. IMU-838 is in Phase 3 clinical trials for relapsing multiple sclerosis, and is also under development for ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935 is targeted for development in psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. IMU-856 is being developed for gastrointestinal diseases such as celiac disease and other conditions involving bowel barrier dysfunction and is entering Phase 2 clinical trials. IMU-381 is a next-generation small molecule in preclinical development for gastrointestinal diseases. The company is headquartered in New York, NY, USA, with research and development activities managed from Gräfelfing, Germany.

Culture

  • Offers flexible working hours
  • Offers hybrid work options
  • Some roles are designated as Remote - US

Technology Story

The company utilizes SPF, DNSSEC, SSL by Default, IPv6, Microsoft Exchange Online, Cloudflare CDN, Cloudflare, Office 365 Mail, and Apache. The Associate Director, Clinical Study Lead role requires knowledge of ICH-GCP, applicable FDA, EMA, and local regulatory requirements.

Why Work Here

Immunic Therapeutics is an Equal Opportunity Employer. Employment decisions are based on qualifications, merit, and business needs. The company does not accept unsolicited resumes from external agencies or recruiters.

Benefits and Perks

  • Offers equity
  • Offers bonus
  • Compensation for the Associate Director, Clinical Study Lead role ranges from $180,000 to $210,000
  • Grants for public transport
  • Grants for fitness
  • Company pension
  • Access to childcare through a membership at BioKids Martinsried

Tech Stack

web_servermxserver

Similar Companies